ENBIO Co., Ltd

ENBIO Co., Ltd

KKRX:352940
1,955.00
KRW
+31.00
(+1.61%)
53.63EPS
37.48P/E
21.84BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
136,062.13
14,945.51
4,179.16
3,145.58
3,150.95
3,132.24
3,258.28
3,134.71
3,377.42
Basic EPS, GAAP
-36,312.99
452
-538
493
-317
-580
59
93
53.63
Free Cash Flow per Basic Share
-7,360.77
-1,145.82
327.01
-359.09
-882.2
908.12
-357.57
185.42
-561.61
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-283.27
2,803.35
3,664.46
4,592.98
4,277.66
3,747.43
3,806.84
3,897.57
4,096.78
Tangible Book Value per Share
-716.24
2,330.3
3,238.97
4,269.26
3,983.66
3,554.95
3,686.81
3,809.2
4,013.44
Basic Weighted Avg Shares
- -
2
8
11
11
11
11
11
11
Sales/Revenue/Turnover
30,328
33,736
34,563
33,466
34,240
34,024
35,654
33,953
36,183
Operating Margin (%)
4.75
13.19
11.85
3.35
-13.95
-9.86
3.94
2.7
3.4
Depreciation Expense
1,829
1,914
2,177
2,289
2,239
2,607
1,779
1,646
- -
Net Income, GAAP
-8,094
1,020
-4,449
5,245
-3,445
-6,300
646
1,007
575
Effective Tax Rate (%)
- -
13.41
- -
14.41
- -
- -
27.02
16.1
11.83
Profit Margin (%)
-26.69
3.02
-12.87
15.67
-10.06
-18.52
1.81
2.97
1.59
Working Capital
-10,235
12,037
20,213
32,472
29,008
21,502
18,515
14,600
18,981
LT Debt
10,853
1,229
1,129
2,167
1,815
516
4,446
5,171
7,986
Total Equity
-2,857
28,270
36,954
49,915
46,488
40,726
41,372
42,358
44,523
Return on Invested Capital (%)
- -
11.56
- -
1.65
- -
- -
1.93
1.42
1.68
Return on Capital (%)
- -
9.11
- -
9.91
- -
- -
2.04
2.7
0.89
Return on Common Equity (%)
- -
- -
-13.64
12.08
-7.15
-14.45
1.57
2.41
1.3

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,885
9,696
16,486
LT Borrowings
4,804
9,140
7,625
LT Finance Leases
367
310
360
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
24,724
23,040
21,844

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
36,204
42,148
45,343
Cash, Cash Equivalents & STI
4,979
2,224
4,692
Accounts Receivable, Net
12,866
- -
- -
Inventories
14,852
16,422
13,737
Total Current Liabilities
21,604
20,127
26,362
Payables & Accruals
- -
- -
- -
ST Debt
8,885
9,696
16,486
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.95%
2.38%
Free Cash Flow
- -
-116.85%
-151.33%
Net Income, GAAP
- -
-70.98%
56.02%
Sales/Revenue/Turnover
- -
-0.29%
-4.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,611
8,837
6,041
5,165
35,654
2025
13,830
8,525
3,936
7,661
33,953
2026
14,141
10,445
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
251
34
-57
-169.45
59
2025
222
17
-101.96
-44.39
93
2026
202.99
-4
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Myung-Jae Lee
Full Time Employees
158
Sector
Process industries
Industry
Chemicals: agricultural
Address
Gunpo-si South Korea
IPO Date
Dec 11, 2020
Business
ENBIO Co., Ltd. is a South Korea-based agricultural chemical and biotechnology company primarily engaged in the research, development, manufacturing, and distribution of crop protection products and specialized agricultural materials. Founded in 1997 and headquartered in Gunpo-si, Gyeonggi-do, South Korea, the company develops eco-friendly and synthetic chemical formulations designed to protect crop yields and manage plant pathogens, pest infestations, and weed competition across diverse agricultural environments. The company categorizes its primary operations into several core product segments: fungicides, including proprietary formulations such as Garujabi, Golden Balance, Gyunstyle, Napoleon, Barosen, Rotiple, and Rommel, designed to control crop diseases such as anthracnose and powdery mildew; insecticides, comprising products such as Gangcheolbi, Gongseup, Ggakjiside, Nabang Plus, Dongjakgeuman, New Jeungwongun, Daytona, Manneungkey, and Mobenking for pest and vector control; herbicides, including selective and non-selective weed control agents such as Gangchota, Golden Age, Nonaeda, Nonejoa, Deopuresen, Debunol, Mantis, Blackout, Salcho-N, and Inbio Bentazone; eco-friendly crop protection agents and biopesticides, centered on proprietary lime-sulfur compound technologies and organic disease control solutions; and plant growth regulators alongside micronutrient compound fertilizers engineered to enhance crop vitality and soil productivity. ENBIO supplies its products across South Korea through primary agricultural distribution networks, including NongHyup Economic Holdings, regional unit agricultural cooperatives, and independent wholesale and retail dealers. Internationally, the company maintains active export channels to markets across Asia and Central Asia, including Uzbekistan, China, and Pakistan. In recent operational and strategic developments, ENBIO has advanced the commercialization of its proprietary novel fungicide compounds developed in collaboration with national research initiatives backed by the South Korean Ministry of Trade, Industry and Energy, targeting international licensing and commercial distribution. The company has substantially expanded its sales penetration through the domestic NongHyup cooperative network, contributing to double-digit revenue expansion driven by herbicide and fungicide export volumes. Additionally, ENBIO implemented key governance and executive changes, including the appointment of Lee Hyeok-jae as Chief Executive Officer in mid-2026 and the institutional restructuring of internal compliance and financial disclosure control systems to support ongoing corporate expansion.